Acute effect of antiseizure drugs on background oscillations in Scn1aA1783V Dravet syndrome mouse model
Abstract
ObjectiveDravet syndrome (Dravet) is a rare and severe form of developmental epileptic encephalopathy. First-line treatment for DS patients includes valproic acid (VA) or clobazam with or without stiripentol (CLB+STP), while sodium channel blockers like carbamazepine (CBZ) or lamotrigine (LTG) are contraindicated. As patients are rarely seizure-free, drug therapy focuses on reducing the seizure burden, as reported by caregivers. In addition to their effect on epileptic phenotypes, antiseizure medications (ASMs) were shown to modify the properties of background neuronal activity. Nevertheless, little is known about these background properties alternations in Dravet. MethodsUtilizing Dravet mice (DS, Scn1aA1783V/WT), we tested the acute effect of several ASMs on background electrocorticography (ECoG) activity and frequency of interictal spikes. ResultsCompared to wild-type mice, background ECoG activity in DS had lower power and reduced phase coherence, which was not corrected by any of the tested ASMs. However, acute administration of Dravet-recommended drugs, including VA or a combination of CLB+STP, caused, in most mice, a reduction of frequency of interictal spikes, alongside an increase in the relative contribution of the beta frequency band. Conversely, CBZ and LTG increased the frequency of interictal spikes with no effect on background spectral properties. Moreover, we uncovered a correlation between the reduction in interictal spike frequency, the drug-induced effect on the power of background activity, and a spectral shift toward higher frequency bands. SignificanceThese data provide a comprehensive analysis of the effect of selected ASMs on the properties of background neuronal oscillations and highlight a possible correlation between their effect on epilepsy and background activity. Thus, examining these properties, following an acute administration, may be used as an additional tool for rapid evaluation of the therapeutic potential of ASMs. Key PointsO_LIReduced background power and phase coherence in Dravet mice C_LIO_LIDS-recommended medicines (VA, CLB+STP) increase the relative beta power C_LIO_LIDS-contraindicated drugs (CBZ, LTG) do not cause spectral changes C_LIO_LICorrelation between reduction in background power and interictal spike frequency C_LIO_LICorrelation between theta to beta bands ratio and interictal spike frequency C_LI
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 8
- FWCI
- 1.63
- Field percentile
- top 19%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Evaluation of spontaneous seizure activity, sex-dependent differences, behavioral comorbidities, and alterations in CA1 neuron firing properties in a mouse model of Dravet Syndrome
C. D. Pernici, A. Spink, … K. S. Wilcox·bioRxiv·Jun 16, 2021
- Testing of putative antiseizure drugs in a preclinical Dravet syndrome zebrafish model
Paige Whyte‐Fagundes, A Vance, … Scott C. Baraban·bioRxiv·Nov 11, 2023
- NaV1.1 and NaV1.6 selective compounds reduce the behavior phenotype in a novel zebrafish model for Dravet Syndrome
Wout J. Weuring, Sakshi Singh, … Bobby P.C. Koeleman·PLoS ONEPeer-reviewed·Mar 5, 2020
- Development of a preclinical screening platform for clinically relevant therapy of Dravet syndrome
Jeffrey A. Mensah, Kyle E. Thomson, … Karen S. Wilcox·EpilepsiaPeer-reviewed·Jun 30, 2025
- Medial septum parvalbumin-expressing inhibitory neurons are impaired in a mouse model of Dravet Syndrome
Limei Zhu, Yiannos Demetriou, … Joanna Mattis·EpilepsiaPeer-reviewed·Jul 7, 2025
- Investigating the Influence of Anti-Seizure Medications on Aperiodic EEG Activity
Marissa M. Holden, Isabella Premoli, … Nigel C. Rogasch·Clinical NeurophysiologyPeer-reviewed·Sep 3, 2026